We showed that (1): tumor-bearing recipients diverged into R, SP, or NR upon anti-PD-L1 treatment (2); Responses to anti-PD-L1 absolutely required CD8 T-cells and correlated positively with effector polyfunctionality of CD8 TILs (3); A similar extent of clonal expansion was observed in the TCR repertoires of CD8 TILs regardless of R vs. NR status (4); The top expanded TCR clonotypes were almost mutually exclusive between R and NR, demonstrating preferential expansion of distinct TCR clonotypes in R vs. NR. This evidence concerns the gene CD8A and neoplasm.